828 related articles for article (PubMed ID: 20151785)
1. Dosing, efficacy and safety plus the use of computerized photography for botulinum toxins type A for upper facial lines.
Lowe NJ; Shah A; Lowe PL; Patnaik R
J Cosmet Laser Ther; 2010 Apr; 12(2):106-11. PubMed ID: 20151785
[TBL] [Abstract][Full Text] [Related]
2. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet.
Lowe NJ; Lask G; Yamauchi P; Moore D
J Am Acad Dermatol; 2002 Dec; 47(6):834-40. PubMed ID: 12451366
[TBL] [Abstract][Full Text] [Related]
3. Remodeling of periorbital, temporal, glabellar, and crow's feet areas with hyaluronic acid and botulinum toxin.
Beer KR; Julius H; Dunn M; Wilson F
J Cosmet Dermatol; 2014 Jun; 13(2):143-50. PubMed ID: 24910278
[TBL] [Abstract][Full Text] [Related]
4. Adverse Events of Botulinum Toxin Type A in Facial Rejuvenation: A Systematic Review and Meta-Analysis.
Jia Z; Lu H; Yang X; Jin X; Wu R; Zhao J; Chen L; Qi Z
Aesthetic Plast Surg; 2016 Oct; 40(5):769-77. PubMed ID: 27495260
[TBL] [Abstract][Full Text] [Related]
5. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet.
Lowe NJ; Ascher B; Heckmann M; Kumar C; Fraczek S; Eadie N;
Dermatol Surg; 2005 Mar; 31(3):257-62. PubMed ID: 15841623
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing.
Lowe NJ; Yamauchi PS; Lask GP; Patnaik R; Moore D
J Cosmet Laser Ther; 2002 Mar; 4(1):15-8. PubMed ID: 12079632
[TBL] [Abstract][Full Text] [Related]
7. RimabotulinumtoxinB vs. onabotulinumtoxinA for the treatment of forehead lines: an evaluator-blind, randomized, pilot study.
Lee DH; Kang SM; Feneran A; Youn CS; Kim JK; Cho S; Won CH; Chang SE; Lee MW; Choi JH; Moon KC
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e1-7. PubMed ID: 23030660
[TBL] [Abstract][Full Text] [Related]
8. Sixth nerve palsy following botulinum toxin injection for facial rejuvenation.
Dolar Bilge A; Sadigov F; Salar-Gomceli S
Cutan Ocul Toxicol; 2017 Jun; 36(2):193-194. PubMed ID: 27558865
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products.
Dessy LA; Fallico N; Mazzocchi M; Scuderi N
Am J Clin Dermatol; 2011 Dec; 12(6):377-88. PubMed ID: 21877763
[TBL] [Abstract][Full Text] [Related]
10. Clostridium botulinum type A toxin for the treatment of upper face animation lines: an Iranian experience.
Farahvash MR; Arad S
J Cosmet Dermatol; 2007 Sep; 6(3):152-8. PubMed ID: 17760691
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin type A reconstituted in lidocaine with epinephrine for facial rejuvenation: results of a participant satisfaction survey.
Kim A; Jung J; Pak A
Cutis; 2013 Jul; Suppl():13-8. PubMed ID: 24308152
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin types A and B: comparison of efficacy, duration, and dose-ranging studies for the treatment of facial rhytides and hyperhidrosis.
Yamauchi PS; Lowe NJ
Clin Dermatol; 2004; 22(1):34-9. PubMed ID: 15158543
[TBL] [Abstract][Full Text] [Related]
13. Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy.
Hexsel D; Brum C; Porto MD; Soirefmann M; Siega C; Schilling-Souza J; Rodrigues TC
J Drugs Dermatol; 2013 Dec; 12(12):1356-62. PubMed ID: 24301236
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Prabotulinumtoxin A and Onabotulinumtoxin A for Crow's Feet: A Phase 3, Multicenter, Randomized, Double-Blind, Split-Face Study.
Cheon HI; Jung N; Won CH; Kim BJ; Lee YW
Dermatol Surg; 2019 Dec; 45(12):1610-1619. PubMed ID: 30893169
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study.
Ascher B; Rzany BJ; Grover R
Dermatol Surg; 2009 Oct; 35(10):1478-86. PubMed ID: 19686365
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines.
Ascher B; Zakine B; Kestemont P; Baspeyras M; Bougara A; Santini J
J Am Acad Dermatol; 2004 Aug; 51(2):223-33. PubMed ID: 15280841
[TBL] [Abstract][Full Text] [Related]
17. The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients.
Blitzer A; Binder WJ; Aviv JE; Keen MS; Brin MF
Arch Otolaryngol Head Neck Surg; 1997 Apr; 123(4):389-92. PubMed ID: 9109785
[TBL] [Abstract][Full Text] [Related]
18. An in vivo analysis of the effect and duration of treatment with botulinum toxin type A using digital image speckle correlation.
Bhatnagar D; Conkling N; Rafailovich M; Phillips BT; Bui DT; Khan SU; Dagum AB
Skin Res Technol; 2013 Aug; 19(3):220-9. PubMed ID: 23565582
[TBL] [Abstract][Full Text] [Related]
19. Botulinum A toxin (BOTOX) in the lower eyelid: dose-finding study.
Flynn TC; Carruthers JA; Carruthers JA; Clark RE
Dermatol Surg; 2003 Sep; 29(9):943-50; discussion 950-1. PubMed ID: 12930337
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin type A for facial rejuvenation. United States and United Kingdom perspectives.
Lowe NJ
Dermatol Surg; 1998 Nov; 24(11):1216-8. PubMed ID: 9834741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
